A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2004
10/28/2004	WO2004058140A3 Non-pegylated long-circulating liposomes
10/28/2004	WO2004056363A3 A physically and chemically stable nicotine-containing particulate material
10/28/2004	WO2004054558A3 Reduction of breast density with 4-hydroxy tamoxifen
10/28/2004	WO2004048328A3 N-arylsulfonyl-3-aminoalkoxyindoles
10/28/2004	WO2004047925A3 Therapeutic oxidation catalysts
10/28/2004	WO2004047838A3 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
10/28/2004	WO2004047766A3 Treatment for sma disease
10/28/2004	WO2004043359B1 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
10/28/2004	WO2004041188A3 Compositions and methods for transdermal oxybutynin therapy
10/28/2004	WO2004041151A3 Neuroprotective iron chelators and pharmaceutical compositions comprising them
10/28/2004	WO2004032874A3 AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
10/28/2004	WO2004024094A3 Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
10/28/2004	WO2004022099A3 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
10/28/2004	WO2004017913A3 Arginine silicate inositol complex and use thereof
10/28/2004	WO2004014318A3 Levothyroxine compositions and methods
10/28/2004	WO2004004682A3 Stable oily suspension of microgranules
10/28/2004	WO2004004648A3 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
10/28/2004	WO2004000228A3 Methods for preventing and treating microbial infections by modulating transcription factors
10/28/2004	WO2003100005A3 Universal chimera bank
10/28/2004	WO2003095613A3 Nucleic acids, polypeptides, and methods for modulating apoptosis
10/28/2004	WO2003089573A3 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
10/28/2004	WO2003087126A3 Heteroclitic analogs and related methods
10/28/2004	WO2003086298A3 Use of interleukin-19 to treat ovarian cancer
10/28/2004	WO2003080593A8 Hydrophilic polymers-flavonoids conjugates and pharmaceutical compositions comprising them
10/28/2004	WO2003076490A8 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
10/28/2004	WO2003061572A8 Anti-inflammatory formulations
10/28/2004	WO2003026591A3 Modification of feeding behavior
10/28/2004	WO2003022882A3 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
10/28/2004	WO2003020954A3 205p1b5 in treatment and detection of cancer
10/28/2004	WO2003018515A3 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
10/28/2004	WO2001081540A3 Growth factor which acts through erb b-4 rtk
10/28/2004	WO2001039723A3 Triazospiro compounds having nociceptin receptor affinity
10/28/2004	US20040215292 Photodynamic treatment of targeted cells
10/28/2004	US20040215284 Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
10/28/2004	US20040215031 Functionalized silicon compounds and methods for their synthesis and use
10/28/2004	US20040215025 formation of by-products by polymerisation of the alkylating agent is avoided whereby a reduction in the amount of alkylating reagent to be used is made possible; high yields
10/28/2004	US20040215021 Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
10/28/2004	US20040215019 Substituted isoindoles and the e use thereof
10/28/2004	US20040215018 use as selective estrogen receptor modulators, and use in inhibiting bone loss, cardiovascular disease, and breast and uterine carcinoma
10/28/2004	US20040215017 Such as 2-methylpropyl-(4-bromo-3-fluorophenyl)carbamate
10/28/2004	US20040215014 Auroyl cyclic amines for controlling behavior or appetite
10/28/2004	US20040214996 Multimeric peptides/immunoglobulins for use in the treatment of bone disorders
10/28/2004	US20040214990 Transmembrane protein differentially expressed in cancer
10/28/2004	US20040214903 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
10/28/2004	US20040214902 Small molecule antagonists of BCL-2 family proteins
10/28/2004	US20040214901 derivatives which inhibit pancreatic lipase and therefore can be used in combating or preventing obesity and hyperlipaemias
10/28/2004	US20040214900 administration to an infected individual of a C8-C16-alpha,beta-unsaturated aliphatic aldehyde, in particular E-2-dodecenal
10/28/2004	US20040214899 aqueous solutions of citric acid, disodium phosphate and (S)-4-{{3-[2-(dimethylaminoethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, used for prophylaxis of headaches; drug delivery devices; nasal sprays
10/28/2004	US20040214898 administering toremifene, and its pharmaceutically acceptable salt, hydrate, N-oxide or mixtures, as selective estrogen receptor modulators, for prophylaxis of osteoporosis, bone disorders, menopause and/or gynecomastia; antiestrogens
10/28/2004	US20040214897 Uses for 2-amino-2-propane-1,3-diols
10/28/2004	US20040214896 drugs and/or prodrugs such as N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide, used for prophylaxis of inflammatory disorders, cancers, psoriasis, diabetes, autoimmune diseases, hepatitis, graft versus host disease or endometriosis
10/28/2004	US20040214894 adminstering to a patient for suppressing, ameliorating, or treating methionine-induced anemia a threonine or salts; side effect reduction
10/28/2004	US20040214893 tartaric acid, ethanedisulfonic acid, or maleic acid salts of gabapentin; improved aqueous solubility, and dose response properties; for treating brain disorders
10/28/2004	US20040214892 Use of a lactate salt for the treatment and prophylaxis of atherosclerosis
10/28/2004	US20040214891 Method for inhibiting pathogenic bacteria and fungi growth and microbicidal composition
10/28/2004	US20040214890 1,3-diamino-2-hydroxypropane derivatives are useful as inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal
10/28/2004	US20040214889 administering to a patient suffering from bone disorder, a calcilytic compound, such as N-[(2R-Hydroxy-3-[(3-chloro-2-cyano)phenoxy-propyl]-1,1-dimethyl-2-(2-naphthyl)ethyl amine hydrochloride, in conjunction with an effective amount of an anti-resorptive agent.
10/28/2004	US20040214886 for the treatment and/or prophylaxis of diseases, in particular, states of pain and neurodegenerative disorders
10/28/2004	US20040214884 Method for supplementing magnesium in an animal
10/28/2004	US20040214883 Calcium monoaspartate
10/28/2004	US20040214882 Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
10/28/2004	US20040214880 Antitumor agents, anticarcinogenic agents; inhibitors of histone deacetylase; a methyleneaminooxymethyl)-thiophene-2-carboxylic acid (2-amino-phenyl)-amide derivatives; chemical synthesis
10/28/2004	US20040214877 Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
10/28/2004	US20040214876 Tetramerous derivative of indole-3-carbinol with anti-carcinogenic activity and method of synthesis of said derivative
10/28/2004	US20040214875 Imidazolinylmethyl aralkylsulfonamides
10/28/2004	US20040214874 Inhibition of protein-tyrosine kinase cmet to block cancer cell proliferation, oral bioavailibility; 2-(2,6-dichlorophenyl)-4-phenyl-5-(pyrimidin-4yl)-1H-imidazoles
10/28/2004	US20040214873 Administering a therapeutically-effective amount of a glycine B partial agonist to improve learning-memory enhancement, Alzheimer's Disease
10/28/2004	US20040214872 Administering a thiazole-2-thione-5-one derivatives as enzyme inhibitor; anticarcinogenic and antitumor agents
10/28/2004	US20040214871 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester
10/28/2004	US20040214869 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
10/28/2004	US20040214868 Treatment or prevention of type 2 diabetes; chemical synthesis; 2-[ benzoyl]aminopyridine-5-carboxylate derivatives
10/28/2004	US20040214867 Quaternary salts of n-substituted cyclic or acyclic amines as pharmaceuticals
10/28/2004	US20040214866 Antidiabetic agents; dietetics; hypoglycermic agents; stable, high melting crystalline material, suitable for bulk preparation and handling
10/28/2004	US20040214864 Novel compounds
10/28/2004	US20040214863 Use of a nicotinic acetyl-cholinesterase inhibitors such as galanthamine-hydrobromide for treating chronic fatigue syndrome; preventing dementia caused by vascular diseases; passing the blood brain barrier
10/28/2004	US20040214862 A N'-hydroxy-terephthalamide derivatives; histone deacetylase enzyme inhibitors; ANTIPROLIFERATIVE AGENTS; ANTITUMOR AGENTS
10/28/2004	US20040214861 Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
10/28/2004	US20040214860 Method for treating inflammatory bowel disease
10/28/2004	US20040214859 Zolpidem hemitartrate
10/28/2004	US20040214858 For use in short-term therapy of insomnia
10/28/2004	US20040214857 Substituted benzimidazoles and imidazo-[4,5]-pyridines
10/28/2004	US20040214856 Cannabinoid receptor ligands and uses thereof
10/28/2004	US20040214855 Cannabinoid receptor ligands and uses thereof
10/28/2004	US20040214854 Cardiovascular compositions and methods using combinations of anti-platelet agents
10/28/2004	US20040214853 Analgesics; side effect reduction; antidiabetic agents; central nervous system disorders
10/28/2004	US20040214852 Polysubstituted imidazopyridines
10/28/2004	US20040214851 increasing gene expression by contacting with compound comprising imidazoquinoline amine, then contacting with opiod growth factor; pain/scarring reduction
10/28/2004	US20040214850 Useful against multidrug resistant cancer cells
10/28/2004	US20040214849 via injection or intravenous drip
10/28/2004	US20040214847 Anti-first-pass effect compounds
10/28/2004	US20040214846 A heteroaryl carbamic acid, secondary amide or amine, or phthalimidoyl derivatives; prevent from getting the disease or condition; cognitive impairment, Down's syndrome, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, cerebral amyloid angiopathy, neurodegenerative disease
10/28/2004	US20040214845 Barbiturates as integrin antagonists and their use for treating inflammatory diseases
10/28/2004	US20040214844 N4-acylcytosine nucleosides for treatment of viral infections
10/28/2004	US20040214843 Such as spiro(cyclohexane-1-4'-(3',4'-dihydro)quinazolin)-2'(1'H)-one for treatment of T-cell-related diseases, autoimmune diseases, osteoarthritis, multiple sclerosis, osteoporosis, asthma and cancer
10/28/2004	US20040214842 comprises opioid analgesic agent (morphine, codeine, fentanyl, and/or methadone) and compound that binds to SS1 or SS2 subunit of sodium channel, such as tetrodotoxin and saxitoxin; side effect reduction
10/28/2004	US20040214841 Quinazoline derivatives for treatment of tumours
10/28/2004	US20040214839 administering prostaglandin or agonist thereof and type IV selective phosphodiesterase (PDE) inhibitor to induce tolerance to antigens
10/28/2004	US20040214837 such as 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-7-(4-methylpiperazin-1-yl)-2H-pyrazolo[4,3-d]pyrimidine; for treatment of eating disorders and psychological disorders
10/28/2004	US20040214836 Method of treatment of myocardial infarction
10/28/2004	US20040214835 Compounds capable of activating cholinergic receptors

1 ... 4910 4911 4912 4913 4914 4915 4916 4917 4918 4919 4920 4921 4922 4923 4924 4925 4926 4927 4928 4929 4930 ... 7860